<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01617551</url>
  </required_header>
  <id_info>
    <org_study_id>RENO_01</org_study_id>
    <nct_id>NCT01617551</nct_id>
  </id_info>
  <brief_title>Effect of Renal Denervation on NO-mediated Sodium Excretion and Plasma Levels of Vasoactive Hormones</brief_title>
  <acronym>RENO</acronym>
  <official_title>Effect of Renal Denervation on NO-mediated Regulation of Salt- and Water Excretion, Vasoactive Hormones and Tubular Transport Proteins in Patients With Resistant Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regional Hospital Holstebro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Regional Hospital Holstebro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Catheter based renal denervation (CRD) in humans represents a promising new treatment of
      resistant hypertension. CRD is currently investigated as a treatment option in patients with
      resistant hypertension defined as at least 3 antihypertensive drugs (including a diuretic) in
      a randomized, sham-controlled, multicenter trial in Denmark (ReSet). In ReSet, patients are
      randomized to either CRD or a sham procedure with 6 months follow up. The mechanisms by which
      CRD reduce blood pressure are only partly understood and the interaction between renal
      sympathetic nerves and nitric oxide (NO) has not been investigated in humans.

      To Study the interaction between NO and renal sympathetic nerves, we designed the present
      substudy, where the effects of NO-inhibition on renal, hemodynamic and hormonal variables are
      studied before and after CRD.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fractional excretion of sodium after acute L-NMMA treatment</measure>
    <time_frame>1 month before and after CRD</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate (GFR) before and after L-NMMA treatment</measure>
    <time_frame>1 month before and after CRD</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>Renal denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient group randomized to renal denervation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients randomized to sham procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NG-monomethyl-L-arginine (L-NMMA)</intervention_name>
    <description>Acute L-NMMA treatment (4,5 mg/kg loading dose followed by 3 mg/kg sustain infusion for 1 hour)</description>
    <arm_group_label>Renal denervation</arm_group_label>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 30-70 years

          -  Stable antihypertensive treatment for 1-month with at least 3 antihypertensive drugs
             including a diuretic

          -  Day-time ambulatory blood pressure &gt; 145/75 mmHg

        Exclusion Criteria:

          -  Non compliance

          -  Pregnancy/no-anticonception in fertile women

          -  Radiocontrast allergy

          -  Malignancy

          -  Congestive heart failure (EF &lt; 50)

          -  eGFR &lt; 45

          -  Unstable angina pectoris

          -  Recent myocardial infarction or PCI (&lt; 6 mdr)

          -  Secondary hypertension

          -  Renal artery stenosis or multiple renal arteries on CT

          -  Claudication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesper N Bech, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of medical research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jesper N Bech, MD, Ph.D</last_name>
    <phone>+45 41627639</phone>
    <email>jnbech@dadlnet.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dept. of medical research</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jesper N Bech, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2012</study_first_submitted>
  <study_first_submitted_qc>June 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2012</study_first_posted>
  <last_update_submitted>March 1, 2014</last_update_submitted>
  <last_update_submitted_qc>March 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Regional Hospital Holstebro</investigator_affiliation>
    <investigator_full_name>Erling Bjerregaard Pedersen</investigator_full_name>
    <investigator_title>Professor, MD, Dr.Sci.</investigator_title>
  </responsible_party>
  <keyword>Essential hypertension</keyword>
  <keyword>Nitric oxide</keyword>
  <keyword>Renal denervation</keyword>
  <keyword>Sodium</keyword>
  <keyword>GFR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>omega-N-Methylarginine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

